Midatech Pharma Plc (AIM:MTPH), a biotechnology company based in United Kingdom, saw significant share price volatility over the past couple of months on the AIM, rising to the highs of £1.03 and falling to the lows of £0.48. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether MTPH’s current trading price of £0.51 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at MTPH’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. See our latest analysis for MTPH

Is MTPH still cheap?

Great news for investors – MTPH is still trading at a fairly cheap price. I’ve used the price-to-book ratio in this instance because there’s not enough visibility to forecast its cash flows, and its earnings doesn’t seem to reflect its true value. The stock’s ratio of 0.7x is currently well-below the industry average of 6.6x, meaning that it is trading at a cheaper price relative to its peers. What’s more interesting is that, MTPH’s share price is quite stable, which could mean two things: firstly, it may take the share price a while to move to its intrinsic value, and secondly, there may be less chances to buy low in the future once it reaches that value. This is because MTPH’s stock is less volatile than the wider market given its low beta.

Can we expect growth from MTPH?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at MTPH future expectations. In MTPH’s case, its revenues over the next couple of years are expected to double, indicating an incredibly optimistic future ahead. If expense does not increase by the same rate, or higher, this top line growth should lead to stronger cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since MTPH is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on MTPH for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy MTPH. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.